why choose us

First received: October 12, 2022

Clinical Trial: HAIC+Lenvatinib+Tislelizumab vs D-TACE+Lenvatinib+Tislelizumab for Unresectable HCC

Study Status: Completed

Recruit Status: RECRUITING

Condition: Unresectable Hepatocellular Carcinoma

Study Type: INTERVENTIONAL


Official Title: HAIC Combined With Lenvatinib and Tislelizumab Versus D-TACE Combined With Lenvatinib and Tislelizumab in Advanced Unresectable Hepatocellular Carcinoma

Brief Summary: Drug-eluting Bead-Transarterial chemoembolization (D-TACE) is the most widely used palliative treatment for hepatocellular carcinoma (HCC) patients.While a number of studies demonstrate poor effect of D-TACE for patients in Advanced Unresectable HCC.The investigators previous study also revealed similar results in Advanced Unresectable HCC patients treated with D-TACE.Recently, the investigators previous study demonstrated that, compared with D-TACE, hepatic arterial infusion chemotherapy (HAIC) may improve tumor…

Read more